BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease. According to GlobalData, Phase I drugs for Cardiovascular Disease have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BR-6002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BR-6002 overview
BR-6002 is under development for the treatment of cardiovascular disease, gastric ulcers and duodenal ulcers. It is administered through oral route.
Boryung Pharmaceutical overview
Boryung Pharmaceutical (Boryung)is a pharmaceutical company. It manufactures and distributes pharmaceutical products including cardiovascular, anticancer and gastrointestinal drugs. The company offers products such as kanarb, gelfos, maxpim injection, mayact tablet, among others. The company’s product portfolio focusses on the chronical diseases including hypertension, dyslipidemia, diabetes, CNS disorders, and cancers. It also offers products including Dukarb Plus, Zepzelca, Finjuve Spray, among others. The company also provides marketed API along with anti-cancer injection facilities. Boryung is headquartered in Seoul, South Korea.
For a complete picture of BR-6002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
